We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Drugs Trigger Compulsive Gambling

By Biotechdaily staff writers
Posted on 02 Aug 2005
Drugs called dopamine agonists that are used to treat patients with Parkinson's disease have been found to be associated with habitual, compulsive gambling and large losses of money by people who previously never or only occasionally gambled.

Doctors at the Mayo Clinic (Rochester, MN, USA) learned about the gambling of 11 patients during routine clinic visits. More...
Four of the patients had never gambled before starting dopamine agonist treatment. "Most of the time, the patient came in for a routine exam and would sheepishly admit ‘I've been gambling too much,' or family members would mention that a loved one had been gambling excessively, that this behavior was totally out of character for them, and that gambling was causing problems in their lives,” said Dr. M. Leann Dodd, a Mayo Clinic psychiatrist. Losses of up to $200,000 were reported.

Researchers assessed the relationship of the gambling behavior to the patients' medications and found that all were taking dopamine agonist medications at levels appropriate for Parkinson's treatments. Eight of the patients were also taking the drug carbidopa/levodopa. The researchers located case reports in medical literature associating Parkinson's disease treatment with pathologic gambling, and compared their patients' experiences with those reported in the literature. This revealed that some patients stopped gambling when the use of a dopamine agonist was discontinued.

In seven patients, pathologic gambling developed within one to three months of reaching the maintenance dose or with dose escalation of dopamine agonist treatment. None of the patients reported compulsive gambling while treated with carbidopa/levodopa alone. The other four patients reported compulsive gambling 12-30 months after starting dopamine agonist therapy. Excessive gambling abated in all four within months of discontinuing dopamine agonist treatment. Six of the patients developed additional behavioral issues that subsided when they quit the dopamine agonist medication, including compulsive eating with weight gain, increased alcohol consumption, and hypersexuality.

The dopamine agonist drugs associated with pathologic gambling appear to be those that specifically target the D3 dopamine receptors, according to Dr. Dodd. These receptors are located in the limbic system of the brain, which controls the emotions, affect, and one's internal "reward system.” When this area of the brain is overstimulated, it can lead to more impulsive behaviors and produce a feeling of pleasure from even a previously undesirable activity, such as compulsive gambling or alcohol consumption.

The Mayo Clinic researchers explain that because pathologic gambling is so infrequently associated with dopamine agonist treatment, this potential side effect would not be a reason to stop prescribing it. Instead, doctors should urge patients to be very candid about gambling or other problems that may arise after starting medication. These findings appeared in the July 2005 issue of Archives of Neurology.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.